Andere talen Theralase Technologies Inc.

Aandelen

TLT

CA88337V1004

Beurs gesloten - Toronto S.E. Andere beurzen 21:59:01 07-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,16 ^CAD	-3,03%		+3,23%	-8,57%

05/04	Theralase Technologies Inc. Ontvangt Canadees patent voor een kanker vaccin	CI
27/03	Theralase Technologies Inc. rapporteert resultaten voor het volledige jaar eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Theralase Technologies Inc. announced that it has received CAD 0.7502 million in funding	24/04
Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent	05/04
Theralase Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Theralase Technologies Donates Cool Laser Therapy Technology to Aid in R&D of Treatment for Parkinson's Disease	12/02
Theralase Technologies shares update on Phase II Bladder Cancer study	08/02
Theralase Technologies Closes C$1.2-Million Private Placement of Share Units	05/02
Theralase Technologies Inc. announced that it has received CAD 1.200001 million in funding	05/02
Theralase Technologies Provides Update on Phase II Bladder Cancer Clinical Study	15/01
Theralase Technologies Inc. Provides Update on Phase II Bladder Cancer Clinical Study	15/01
Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA	04/12
Theralase Technologies Raises C$1.17 Million in a Private Placement of Share Units	29/11
Theralase Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11
Theralase Technologies Inc. announced that it has received CAD 1.17 million in funding	29/11
Theralase Technologies Raising up to C$1.5 Million in a Private Placement of Share Units	17/11
Theralase Technologies Inc. announced that it expects to receive CAD 1.5 million in funding	17/11
Theralase Technologies : Amended LIFE Offering Document	27-10-23
Theralase® Technologies Inc. Announces That It Has Been Granted Clinical Trial Application Amendment by Health Canada Through Receipt of A No Objection Letter for the Optimization of the Phase Ii Non-Muscle Invasive Bladder Cancer Clinical Study	23-10-23
Theralase Technologies Inc. Provides Update on Bladder Cancer Clinical Study	16-10-23
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	09-10-23
Theralase Technologies Inc. Files US Patent for Enhanced Immunotherapy	05-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Theralase Technologies Inc.

Aandelen

TLT

CA88337V1004

Andere talen

Filters